A drug that gives ‘immediate immunity’ to coronaviruses? UK tests new antibody therapy


After exposure to Kovid-19, a new antibody treatment is being given to people with immediate immunity and the ability to prevent disease by scientists in the UK.

This drug will provide immediate and long-term protection to patients when it is too late to offer a vaccine, potentially saving thousands of lives.

It can be given as emergency treatment to hospitalized patients, caregivers and university students in reducing the spread of the virus.

People who live with someone who has caught COVID or come in contact with them can be injected with medication to prevent them from getting infected, even if they do not have a coronovirus vaccine.

British scientists at University College London Hospitals NHS (UCLH) have already injected ten people with the drug as part of a new test called Storm Chaser, which aims to test the new treatment at 1,125 people globally. Participants received two consecutive doses of the drug.

They hope that the treatment will provide protection between Kovid-19 to six months to a year.

After exposure to Kovid-19, a new antibody treatment is being given to people with immediate immunity and the ability to prevent disease by scientists in the UK. Picture above of a patient in a hospital in Houston, Texas

Scientists at UCLH have launched a second clinical trial called Provent to investigate the use of antibodies for people who may not benefit from the vaccine, such as patients with a compromised immune system, or Covid-19 due to increased risk of infection. For factors such as age and current conditions.

UCLH injected ten people – including medical staff and university students – as part of the Storm Chaser test at its new vaccine research center on December 10 after studying in phase three trials.

The major testing groups include healthcare workers, students living in shared housing, and patients who have recently been exposed to someone with Kovid-19, as well as long-term care, military and industry personnel such as That factory worker.

In the first trial, the antibody, known as AZD7442, has been developed by pharmaceutical company AstraZeneca, which has also produced a vaccine with the University of Oxford awaiting approval for use by the Medicines and Healthcare Products Regulatory Agency (MHRA) Has been

Meanwhile, older people and those with long-term care, as well as people with conditions such as cancer and HIV, will also be admitted to participate in the recruitment exam.

UCLH’s virologist who led the storm chaser trial, Drs. Catherine Houlihan said: ‘We know that this antibody combination can neutralize the virus, so we hope that giving this treatment via injection can provide immediate protection against the development of Kovid – in 19 people who are exposed Have come – when it will be too late to give the vaccine. ‘

Dr. Houlihan said the treatment would be an ‘exciting addition’ to efforts to be tested and developed to fight Groviruses, reports The Guardian.

‘If we can prove that this treatment works and prevent people coming into contact with the virus to develop Kovid-19, then it is going to be an arsenal of weapons being developed to fight this terrible virus. Would be an exciting addition, ‘she said.

UCLH Infectious Diseases Consultant Drs. Nikki Longley, who is heading the university’s part of Provent, said: ‘We want to reassure anyone, for whom a vaccine may not work that we can offer an alternative that is only protective .

Paul Hunter, a professor of medicine and infectious diseases specialist at the University of East Anglia, said the new treatment in the Storm Chaser trial could save thousands of lives.

‘If you are dealing with an outbreak in settings such as care homes, or if you have found patients who are particularly at risk of severe covariates, such as the elderly, it can save a lot of lives. Providing this is born in Phase 3 trials, it can play a big role in keeping survivors who would otherwise die. So it should be a big deal, ‘he said.

‘If you had an outbreak in the care home, you could use these types of cocktails of antibodies to get residents and staff under control as soon as possible by giving the medicine to everyone in the care home. T was vaccinated.

‘Similarly, if you live with your elderly grandmother and you or someone else in the house gets infected, you can give it to her to protect her.’

The potential success in immediate immune treatment is welcome news in the US and around the world as approximately 119,000 Americans spent Christmas Day in hospital with COVID-19 and 1,541 more deaths were recorded.

But according to the COVID tracking project, 20 states did not provide any updates on their numbers on Friday, meaning the exact number of deaths nationwide could be far higher.

While the overall hospital declined 118,948 on Friday, setting a new record of 120,151 the previous day, the seven-day average climbed to a new high on Christmas day, reaching 117,029.

On Friday, 124,498 new cases were reported, yet the COVID tracking project warned that data had been affected by the expiration of the holiday.

The seven-day average for hospitalization climbed to a new high on Christmas day, reaching 117,029 as approximately 1119,000 COVID-19 patients spent in hospital leave

The seven-day average for hospitalization climbed to a new high on Christmas day, reaching 117,029 as approximately 1119,000 COVID-19 patients spent in hospital leave

Nationwide, there are more than 18.7 million Americans infected with coronovirus and 330,246 deaths.

Among the states that did not provide any updates on new cases and deaths on Friday was California, where the outbreak has already brought the healthcare system to breaking point after reporting 300,000 new cases last week.

Earlier this week, it became the first state to cross two million cases as experts remain concerned about a possible spike by Christmas and New Year commuters.

.

Leave a Reply

Your email address will not be published.